Cyclacel Pharmaceuticals Q2 EPS $(0.44) Beats $(0.50) Estimate, Sales $373.00K
Portfolio Pulse from sunil@benzinga.com
Cyclacel Pharmaceuticals reported Q2 losses of $(0.44) per share, beating the analyst consensus estimate of $(0.50) by 12 percent. This is a 4.35 percent increase over losses from the same period last year. The company reported $373.00 thousand in sales this quarter.
August 09, 2023 | 9:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cyclacel Pharmaceuticals reported better than expected Q2 earnings, with losses per share of $(0.44), beating estimates by 12%. Sales were $373.00K.
Cyclacel Pharmaceuticals reported better than expected Q2 earnings, which is generally a positive signal for the stock. The company's losses per share were less than the analyst consensus estimate, indicating improved financial performance. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100